Search / 95 results found

from
to
  • Updated

Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of Jan. 24 to 28, 2022. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.

  • Updated

FRIDAY, Jan. 28, 2022 (HealthDay News) -- Receipt of three doses of an mRNA COVID-19 vaccine is associated with protection against delta and omicron compared with being unvaccinated and receipt of two doses, according to a study published online Jan. 21 in the Journal of the American Medical Association.

FRIDAY, Jan. 28, 2022 (HealthDay News) -- Neutralization titers against the omicron variant are lower than those against the D614G variant following the primary two-dose series of the mRNA-1273 vaccine, but a booster dose of mRNA-1273 vaccine substantially increases them, according to a letter to the editor published online Jan. 26 in the New England Journal of Medicine.

  • Updated

THURSDAY, Jan. 27, 2022 (HealthDay News) -- Receipt of a third COVID-19 mRNA vaccine dose is associated with increased vaccine effectiveness against COVID-19 hospitalization, according to research published in the Jan. 28 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

  • Updated

THURSDAY, Jan. 27, 2022 (HealthDay News) -- Moderna Inc. announced Wednesday that it has launched a trial that will study the power of a redesigned booster shot -- one that homes in on the highly contagious omicron variant.

  • Updated

THURSDAY, Jan. 27, 2022 (HealthDay News) -- Despite a low absolute risk, there is an increased relative risk for carditis associated with BNT162b2 (Pfizer-BioNTech) vaccination, particularly among men and adolescents, according to a study published online Jan. 25 in the Annals of Internal Medicine.

  • Updated

THURSDAY, Jan. 27, 2022 (HealthDay News) -- Moderna Inc. announced Wednesday that it has launched a trial that will study the power of a redesigned booster shot -- one that hones in on the highly contagious Omicron variant.

  • Updated

WEDNESDAY, Jan. 26, 2022 (HealthDay News) -- Booster doses seem effective for the severe acute respiratory syndrome coronavirus 2 omicron variant, according to research published in the Jan. 21 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

  • Updated

TUESDAY, Jan. 25, 2022 (HealthDay News) -- Pfizer Inc. announced Tuesday that it has launched a trial that will compare its existing COVID-19 vaccine against a new version tailored to beat back the highly contagious omicron variant.